论文部分内容阅读
0引言恩替卡韦(entecavir ETV)为鸟嘌呤核苷类似物,对乙型肝炎病毒(hepatitis HBV)具有较强的抑制作用以及它极低的耐药率,使之成为慢性乙型病毒性肝炎及其后期重要的一线治疗药物,可以长期保护患者远离耐药困扰,强效持久地控制病情。我们在临床工作中对1例初治的乙肝肝硬化患者进行动态随访,该患者抗病毒采用恩替卡韦分散片和恩替卡韦交替服用期间出现病毒学反弹,并于外院经基因耐药检测提示为恩替卡
0 Introduction Entecavir ETV is a guanosine nucleotide analog that has a strong inhibitory effect on hepatitis B virus and its very low resistance rate making it a chronic hepatitis B virus and its Late important front-line treatment of drugs, can long-term protection of patients from drug resistance problems, a strong and lasting control of the disease. We conducted a clinical follow-up of a newly diagnosed hepatitis B cirrhosis patient who had antiviral rebound during antiviral use of entecavir dispersible tablets and entecavir, and the drug resistance test in the outer court suggested that entecavir